SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a significant surge amid widespread rumors of an impending partnership with Novo Nordisk to sell obesity drugs on its platform, fueling intense short squeeze speculation due to high short interest and renewed optimism around its expanding peptide offerings.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership with Hims & Hers to sell obesity drugs, a move the community views as trapping shorts and signaling a major turnaround. This development, coupled with rapidly accelerating adoption of its oral Wegovy and a recent FDA crackdown on compounded GLP-1s, has many calling the stock a generational buying opportunity despite past competitive pressures.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is seeing immense upward pressure as escalating geopolitical tensions in the Middle East have effectively disrupted shipping through the critical Strait of Hormuz, causing widespread concerns about global oil supply. The community is actively discussing the potential for significantly higher crude prices, viewing the situation as a genuine supply 'plumbing break' rather than just a fleeting fear-driven rally.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

SKR (Seeker), a Solana Smartphone Token, is trending following recent exchange listings and an incentive offering a discount for purchases made with SKR. The community is keenly focused on breaching a key price resistance level amid high trading volume, with anticipation for future catalysts balanced by warnings of potential sell-offs from early participants.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group ($DJT) is trending amidst intense community discussion following the release of new Epstein files containing sexual assault allegations against Donald Trump, alongside widespread concern over the ongoing conflict with Iran and its perceived negative impact on the economy and gas prices.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending following news of an AI licensing partnership in Africa, sparking intense community discussion and predictions of a significant short squeeze driven by its notably low float and high cost to borrow.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is highly volatile amid escalating Middle East tensions driving oil prices higher and intensifying inflation concerns, leading the community to debate potential market downturns and Federal Reserve policy implications.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

Heightened geopolitical tensions surrounding Iran, rising oil prices, and a recent weaker jobs report are driving IWM's trend, as the community actively debates whether these catalysts signal a significant downturn for small-cap stocks or a strategic buying opportunity. Traders are closely monitoring IWM's key price levels, recognizing its role as a highly volatile bellwether for overall market sentiment amid global uncertainty.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending as community speculation mounts that the departure of a key FDA official may pave an easier regulatory path for its Huntington's disease gene therapy, fueling a significant rally and short squeeze chatter after prior data concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +64.44% and +2.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of -1.00% and +1.55%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Insider Selling: Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) insider J. Jefferson Smith sold 4,925 shares of the company's stock in a transaction on Wednesday, February 18th. The shares were sold at...

Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) insider J. Jefferson Smith sold 4,925 shares of the firm's stock in a transaction dated Wednesday, February 18th. The shares were sold at...

John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) CFO John Alexander Kelly sold 8,149 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The shares...

Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) CEO Michael Amoroso sold 20,559 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold...

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Update

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totaling 1,323,402...

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Current Price	$4.61
Prev Close	$4.53
Open	$4.49
Dividend Yield	0.00%
50-Day Moving Average	$4.08
Beta	0.76
Avg. Volume	197,857.01
PE Ratio	-0.54

52-Week High	$8.82
52-Week Low	$3.53
Market Capitalization	$109.17M
EPS (Annual)	$1.04
Price to Book	3.29
Revenue Per Employee	$636,074.07

DTIL
Precision Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DTIL News

DTILPrecision Biosciences Inc